Top-News
Werbung

Attraktive Knock-Outs auf Sanofi SA

Typ Hebel Bid / Ask WKN
Call
5,0 1,81 € / 1,84 €
SN5672
Call
9,9 0,91 € / 0,94 €
SN567W
Typ Hebel Bid / Ask WKN
Put
4,9 1,85 € / 1,88 €
SH4RDM
Put
12,1 0,74 € / 0,77 €
SU3BX8
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA
Pharmazeutika Frankreich

Sanofi SA News

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF
91,13 €
-0,90 €
-0,98%
03.05.24 21:55:01
Handeln Depot/Watchlist
Aktienanzahl *
1,25 Mrd.
Marktkapitalisierung *
115,25 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Euro Stoxx 50
IR-Website
zur Website
*Stand: 25.04.2024
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,29: ME2BPF

Ad-hocs

02.05.24 - GlobeNewswire
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-​world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
30.04.24 - GlobeNewswire
Press Release: Annual General Meeting of April 30, 2024
Annual General Meeting of April 30, 2024
25.04.24 - GlobeNewswire
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
23.04.24 - GlobeNewswire
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
17.04.24 - GlobeNewswire
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
22.03.24 - GlobeNewswire
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
Availability of the Q1 2024 Memorandum for modelling purposes
11.03.24 - GlobeNewswire
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
New Phase 2b results for amlitelimab support potential for best-​in-class maintenance of response in atopic dermatitis
24.02.24 - GlobeNewswire
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
23.02.24 - GlobeNewswire
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
23.02.24 - GlobeNewswire
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
22.02.24 - GlobeNewswire
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
16.02.24 - GlobeNewswire
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU)
15.02.24 - GlobeNewswire
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
Phase 2 data published in NEJM show potential of frexalimab as high-​efficacy therapy in relapsing MS
05.02.24 - GlobeNewswire
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
01.02.24 - GlobeNewswire
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
François-​Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
01.02.24 - GlobeNewswire
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
25.01.24 - GlobeNewswire
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
23.01.24 - GlobeNewswire
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Sanofi to acquire Inhibrx, Inc., adding potential best-​in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth strategy ...
09.01.24 - GlobeNewswire
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee Paris, January 9, 2024 . Brian Foard, a healthcare industry veteran and ...
21.12.23 - GlobeNewswire
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »